The Gut-brain Axis: a Novel Target for Treating Behavioral Alterations in Obesity

Completed · Not applicable · Has a placebo group

Conditions studied: Neural Response in Caudate, Weight Loss Trial, Impulsivity

In brief

The aims of this project are to determine if dietary supplementation with NOPE-EGCG (PhosphoLeantm, 30mg NOPE+20mg EGCG per capsule) can: * rescue striatal function, * increase adherence to a diet, * reduce weight-gain after a diet, * improve performance on impulsivity, go/no-go tasks, and negative outcome learning, and * shift fat and sweet preference in overweight/obese human subjects Secondary hypotheses: Baseline brain; perceptual and cognitive measures will be associated with diet, insulin sensitivity and may vary with genotype (TaqA1 1A polymorphism).

Key facts

Study ID
NCT01976156
Run by
Yale University
People needed
100
Starts
2013-10-01
Expected to finish
2017-10-01
Last updated by the study team
2018-06-27

Who can join

Age: 18 and older, up to 45. Sex: any. Healthy volunteers: accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.